Trials / Completed
CompletedNCT01874431
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 823 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess a new drug, BAY94-8862 given orally at different doses, to evaluate whether it was safe and can help the well being of patients with type 2 diabetes and diabetic nephropathy. These treatment doses were compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Finerenone (BAY94-8862) | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-06-12
- Primary completion
- 2014-07-09
- Completion
- 2014-08-07
- First posted
- 2013-06-11
- Last updated
- 2021-07-01
- Results posted
- 2021-05-04
Locations
147 sites across 23 countries: United States, Australia, Austria, Bulgaria, Canada, Czechia, Denmark, Finland, France, Germany, Hong Kong, Hungary, Israel, Italy, Netherlands, Norway, Poland, Portugal, South Africa, South Korea, Spain, Sweden, Taiwan
Source: ClinicalTrials.gov record NCT01874431. Inclusion in this directory is not an endorsement.